The gut microbiota features of patients with type 1 myocardial infarction with ST segment elevation
- 作者: Stepanov M.S.1,2, Karpunina N.S.1, Godovalov A.P.1,3, Ipatova N.V.1
-
隶属关系:
- Academician Ye.A. Vagner Perm State Medical University
- Clinical Cardiology Dispensary
- Medical Unit of the Ministry of Internal Affairs of Russia for Perm Krai
- 期: 卷 15, 编号 4 (2025)
- 页面: 775-780
- 栏目: SHORT COMMUNICATIONS
- URL: https://journal-vniispk.ru/2220-7619/article/view/352128
- DOI: https://doi.org/10.15789/2220-7619-STG-17832
- ID: 352128
如何引用文章
全文:
详细
The relationship between the colonic biocenosis and the cardiovascular system is a relevant issue that has been thoroughly studied over the past 20 years. Nowadays, it has been proven that the intestinal microflora is able to regulate many host mechanisms, and its quantitative and qualitative changes trigger a cascade of pathological reactions. The main points of application through which the pathological effect is enabled are stimulation of systemic inflammation and lipid metabolism. Type 1 myocardial infarction with ST-segment elevation (STEMI) is the most dangerous form of coronary heart disease, often leading to death and disability. The aim of the study was to identify the features that determine the intraluminal colonic microbiota in patients with type 1 STEMI and estimate blood serum CRP level. The study enrolled 43 patients with type 1 STEMI aged 37 to 59 years. The first portion of feces was collected from and analyzed in patients with STEMI from the onset of clinical manifestations of the cardiovascular event. The control group consisted of age-matched conditionally healthy individuals (n = 41) without a history of ACS. Patients with STEMI are characterized by a reduced number of Bifidobacterium spp., Enterococcus spp. and typical E. coli strains. In main group, non-motile strain of E. coli, Staphylococcus spp. and opportunistic bacteria, especially representatives of the genera Citrobacter and Kluyvera, were more common. In addition, 76% of patients in main group had leukocytosis and absolute monocytosis, and 100% of cases had elevated CRP levels. Thus, the clinical study presents data reflecting the taxonomic characteristics of colonic microbiota in patients with type 1 STEMI and their inflammatory profile. Dynamic observation of such patients seems promising for the long-term assessing interplay between intestinal microbiocenosis, cardiovascular continuum, and human immune system.
作者简介
Maksim Stepanov
Academician Ye.A. Vagner Perm State Medical University; Clinical Cardiology Dispensary
编辑信件的主要联系方式.
Email: maximpractice@gmail.com
Postgraduate student and assistant of hospital therapy and cardiology department; cardiologist
俄罗斯联邦, PermN. Karpunina
Academician Ye.A. Vagner Perm State Medical University
Email: maximpractice@gmail.com
DSc (Medicine), Professor of the Department of Microbiology and Virology
俄罗斯联邦, PermA. Godovalov
Academician Ye.A. Vagner Perm State Medical University; Medical Unit of the Ministry of Internal Affairs of Russia for Perm Krai
Email: maximpractice@gmail.com
PhD (Medicine), Associate Professor, Department of Microbiology and Virology, Bacteriologist
俄罗斯联邦, Perm; PermN. Ipatova
Academician Ye.A. Vagner Perm State Medical University
Email: maximpractice@gmail.com
6th Year Student, Faculty of General Medicine
俄罗斯联邦, Perm参考
- Бухарин О.В., Усвяцов Б.Я., Хлопко Ю.А. Медико-экологические аспекты микросимбиоценоза человека // Экология человека. 2010. Т. 17, № 8. C. 28–31. [Bukharin O.V., Usvyatsov B.Y., Khlopko Y.A. Medico-ecological aspects of human microsymbiocenosis. Ekologiya cheloveka = Human Ecology, 2010, vol. 17, no. 8, pp. 28–31. (In Russ.)]
- Острый коронарный синдром с подъемом сегмента ST электрокардиограммы: клинические рекомендации, 2021. [Acute coronary syndrome with ST-segment elevation: Clinical guidelines, 2021. (In Russ.)] URL: https://www.monikiweb.ru/sites/default/files/page_content_files/KP157.pdf (01.03.2025)
- Al Bander Z., Nitert M.D., Mousa A., Naderpoor N. The Gut Microbiota and Inflammation: An Overview. Int. J. Environ. Res. Public Health, 2020, vol. 17, no. 20: 7618. doi: 10.3390/ijerph17207618
- Bartolomaeus H., Balogh A., Yakoub M., Homann S., Markó L., Höges S., Tsvetkov D., Krannich A., Wundersitz S., Avery E.G., Haase N., Kräker K., Hering L., Maase M., Kusche-Vihrog K., Grandoch M., Fielitz J., Kempa S., Gollasch M., Zhumadilov Z., Kozhakhmetov S., Kushugulova A., Eckardt K.U., Dechend R., Rump L.C., Forslund S.K., Müller D.N., Stegbauer J., Wilck N. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation, 2019, vol. 139, no. 11, pp. 1407–1421. doi: 10.1161/CIRCULATIONAHA.118.036652
- Cui L., Zhao T., Hu H., Zhang W., Hua X. Association Study of Gut Flora in Coronary Heart Disease through High-Throughput Sequencing. BioMed Res. Int., 2017: 3796359. doi: 10.1155/2017/3796359
- Kim S., Goel R., Kumar A., Qi Y., Lobaton G., Hosaka K., Mohammed M., Handberg E.M., Richards E.M., Pepine C.J., Raizada M.K. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin. Sci., 2018, vol. 132, no. 6, pp. 701–718. doi: 10.1042/CS20180087
- Koren O., Spor A., Felin J., Fåk F., Stombaugh J., Tremaroli V., Behre C.J., Knight R., Fagerberg B., Ley R.E., Bäckhed F. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc. Natl Acad. Sci. USA, 2011, vol. 108, suppl. 1, pp. 4592–4598. doi: 10.1073/pnas.1011383107
- Ma Q.Q., Yang X.J., Yang N.Q., Liu L., Li X.D., Zhu K., Fu Q., Wei P. Study on the levels of uric acid and high-sensitivity C-reactive protein in ACS patients and their relationships with the extent of the coronary artery lesion. Eur. Rev. Med. Pharmacol. Sci., 2016, vol. 20, no. 20, pp. 4294–4298. doi: 10.1073/pnas.1011383107
- Mamic P., Chaikijurajai T., Tang W.H. Gut microbiome — A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review. J. Mol. Cell. Cardiol., 2021, vol. 152, pp. 105–117. doi: 10.1016/j.yjmcc.2020.12.001
- Papadopoulos P.D., Tsigalou C., Valsamaki P.N., Konstantinidis T.G., Tsakris A., Karamanou M., Christodoulou C., Gourgoulianis K.I. The Emerging Role of the Gut Microbiome in Cardiovascular Disease: Current Knowledge and Perspectives. Biomedicines, 2022, vol. 10, no. 5: 948. doi: 10.3390/biomedicines10050948
- Piccioni A., de Cunzo T., Valletta F., Covino M., Mangiola F., Franceschi F., Gasbarrini A., Miraldi F. Gut Microbiota and Environment in Coronary Artery Disease. Int. J. Environ. Res. Public Health, 2021, vol. 18, no. 8: 4242. doi: 10.3390/ijerph18084242
- Sanchez-Gimenez R., Peiró Ó.M., Bonet G., Sanchis-Gomar F., Lippi G., Pons-Catalano C., Ferrer J.M., Roldán I., Sanchis J., Chorro F.J., Núñez J., Bodí V., Miñana G. Plasma trimethylamine-N-oxide, its precursors and risk of cardiovascular events in patients with acute coronary syndrome: Mediating effects of renal function. Front. Cardiovasc. Med., 2022, vol. 9: 1000815. doi: 10.3389/fcvm.2022.1000815
- Tenaillon O., Skurnik D., Picard B., Denamur E. The population genetics of commensal Escherichia coli. Nat. Rev. Microbiol., 2010, vol. 8, no. 3, pp. 207–217. doi: 10.1038/nrmicro2298
- Tousoulis D., Guzik T., Padro T., Duncker D.J., Guazzi M., Gori T., Jankowska E.A., Munzel T., Piepoli M.F., Reiner Z., Ruschitzka F., Schirmer S.H., Schutte A.E., Cosentino F. Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation. Cardiovasc. Res., 2022, vol. 118, no. 16, pp. 3171–3182. doi: 10.1093/cvr/cvac057
- Yaratha G., Perloff S., Changala K. Lactose vs Non-Lactose Fermenting E. coli: Epidemiology, Clinical Outcomes, and Resistance. Open Forum Infect. Dis., 2017, vol. 4, suppl. 1, pp. 589–590. doi: 10.1093/ofid/ofx163.1546
- Zhou X., Li J., Guo J., Geng B., Ji W., Zhao Q., Li J., Liu X., Liu J., Guo Z., Zhang L., Chen P., Li Y., Wang Y., Wang Z., Jin M., Xia M., Tang T., Ge J., Zhou S. Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction. Microbiome, 2018, vol. 6, no. 1: 66. doi: 10.1186/s40168-018-0441-4
- Zhu Q., Gao R., Zhang Y., Pan D., Zhu Y., Zhang X., Yang R., Jiang R., Xu Y., Qin H. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol. Genomics, 2018, vol. 50, no. 10, pp. 893–903. doi: 10.1152/physiolgenomics.00070.2018
补充文件


